Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders
November 29 2022 - 8:00AM
Galectin Therapeutics Inc.(NASDAQ:GALT), the
leading developer of therapeutics that target galectin proteins,
announced today that management will present a corporate update via
live webcast immediately following the business portion of its 2022
Annual Meeting of Stockholders to be held on Thursday, December 1,
2022 beginning at 11:00 a.m. ET.
The Annual Meeting of Stockholders and webcast
can be accessed via
www.virtualshareholdermeeting.com/GALT2022.
Please log in approximately 10 minutes before
the event to ensure a timely connection.
About Galectin Therapeutics
Galectin Therapeutics is dedicated to
developing novel therapies to improve the lives of patients with
chronic liver disease and cancer. Galectin’s lead drug belapectin
(formerly known as GR-MD-02) is a carbohydrate-based drug that
inhibits the galectin-3 protein which is directly involved in
multiple inflammatory, fibrotic, and malignant diseases, for which
it has Fast Track designation by the U.S. Food and Drug
Administration for NASH with advanced fibrosis. The lead
development program is in non-alcoholic steatohepatitis (NASH) with
cirrhosis, the most advanced form of NASH-related fibrosis. This is
the most common liver disease and one of the largest drug
development opportunities available today. Additional development
programs are in treatment of combination immunotherapy for advanced
melanoma and other malignancies. Advancement of these additional
clinical programs is largely dependent on finding a suitable
partner. Galectin seeks to leverage extensive scientific and
development expertise as well as established relationships with
external sources to achieve cost-effective and efficient
development. Additional information is available at
www.galectintherapeutics.com..
ContactJack Callicutt, Chief
Financial Officer (678) 620-3186ir@galectintherapeutics.com
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Galectin Therapeutics (NASDAQ:GALT)
Historical Stock Chart
From Jul 2023 to Jul 2024